About - Hospitals - Programs and Services - Outpatient - Locations - Giving
Conemaugh Memorial Offers New Treatment for Men with Advanced Stage Metastatic Prostate Cancer
Home > About Us > Media Center > Press Releases > Conemaugh Memorial Offers New Treatment for Men with Advanced Stage Metastatic Prostate Cancer

Posted: 2013-11-19

Conemaugh Memorial Medical Center is now offering new treatment options for men with advanced stage metastatic prostate cancer, making it the only patient-ready site between State College and Pittsburgh to offer this care. Xofigo, the new prostate therapy system, can relieve pain and reduce fractures as well as prolong life. This technology is the first of its kind to be approved by the Food and Drug Administration.

"This new treatment provides a valuable tool for our staff to help our patients," says Ryan Shawley, Lead Nuclear Medicine Technologist at Conemaugh Memorial. "Prostate cancer is the second leading cause of cancer death in men. Treatments such as Xofigo give us a competitive advantage in the fight against cancer."

Xofigo (radium 223 dichloride) is injected through an intravenous line in the patient’s arm. The radium mimics calcium and is absorbed by the bone. Alpha radiation emitted from the drug results in an anti-tumor effect on bone metastases. The injection takes only a few minutes and within twenty four hours the majority of the injection substance clears from the patient’s bloodstream, resulting in little damage to healthy cells in the patient's body. Patients receive a total of six injections, four weeks apart, on an outpatient basis in the nuclear medicine department.

"Xofigo is a remarkable advancement in our treatment of mestastatic prostate cancer to bone," says Dr. William Wynert, Conemaugh Physician Group - Medical Oncology. "The injections are highly effective and well tolerated. Virtually all prostate cancer patients can receive the drug despite age or additional diseases."

According to the American Cancer Society, over 200,000 men will be diagnosed and almost 30,000 men will likely die from prostate cancer in 2013 in the United States.

For more information, talk with your Medical Oncologist or call Conemaugh Memorial Medical Center Nuclear Medicine at (814) 534-9573. A physician referral is needed to perform this treatment.


About Conemaugh Memorial Medical Center
Conemaugh Memorial Medical Center (MMC), the flagship hospital of the Conemaugh Health System, is a regional referral hospital known for clinical excellence. Memorial has received HealthGrades Distinguished Hospital for Clinical Excellence award for 2012, 2011, 2009, 2008 and 2007, for clinical outcomes which are among the Top 5% in the nation. Learn more at the Conemaugh Health System’s all new website, www.conemaugh.org.

For More Information, Please Contact:
Amy Bradley, Director of Public Affairs
Phone: (814) 534-3121
Email: abradle@conemaugh.org